Skip to main content
. 2022 Feb;13(1):163–170. doi: 10.21037/jgo-21-514

Figure 1.

Figure 1

Waterfall plot demonstrating percentage decrease in tumor burden by mutation status. Asterix (*) depicts three patients (all KRAS-mut) who had disease progression while on HAI chemotherapy (+257%, +30% and +14%). HAI, hepatic arterial infusion; CRLM, colorectal cancer liver metastases.